November 30 - Dec 3, 2018
Westin Boston Waterfront
Boston, Massachusetts, USA
Abstract submission deadline: Monday, September 10
Advance registration deadline: Tuesday, October 16
ACCREDITATION STATEMENTThe American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
CREDIT DESIGNATION STATEMENTAACR has designated this live activity for a maximum of 17.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
CLAIMING (CME) CREDITPhysicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Friday, January 11, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this website and via email. Your CME certificate will be sent to you via email after the completion of the activity.
STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVESGenetic events leading to aberrant activation of the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathway are among the most frequently occurring alterations in human cancers. In normal cells, this pathway responds to growth factors, cytokines, and hormones, such as insulin, and promotes cell growth, proliferation, survival, and metabolism through a variety of downstream targets. Oncogenic mutations in cancer cells activate this pathway in a manner that disconnects its control of these cellular processes from normal growth signals, leading to constitutive activation of the pathway. Cancer genome sequencing efforts combined with numerous preclinical and clinical studies have highlighted the importance of this pathway in cancer development and progression.
From molecular and cell biologic studies, it has become increasingly clear that PI3K is not part of a linear pathway but rather a key component of a broader network of signaling pathways, with intimate connections to the mechanistic target of rapamycin (mTOR) and Ras pathways, among others. PI3K and mTOR are particularly intertwined, with the mTOR protein complexes (mTORC1 and mTORC2), acting as both downstream effectors and central regulators of the pathway. Furthermore, while PI3K is predominantly a lipid kinase and mTOR is a protein kinase, these two proteins are structurally related to each other, such that chemical inhibitors can often directly inhibit the activity of both proteins. mTOR signaling is elevated in the majority of human cancers, and this occurs, in part, through oncogenic activation of the PI3K pathway. The focus of this meeting is on understanding and targeting the PI3K-mTOR network in cancer.
From preclinical models and clinical trials, it is evident that effective pharmaceutical compounds are emerging for cancer therapy. This conference will discuss these recent discoveries in the hopes of bringing even more precise targeted and combination therapies to the clinic.
After participating in this CME activity, physicians should be able to:
1. Articulate the advances in understanding the biology of the PI3k/mTOR pathway.2. Explain how pathway involvement in autophagy/metabolism and control of protein translation can contribute to cancer.3. Provide examples of how structural biology is critical to understanding pathway mechanistic and potential opportunities for therapy.4. Provide examples of preclinical studies using both immunology and drug development to target this pathway.5. Provide an update on existing and planned clinical trials.
DISCLOSURE STATEMENTIt is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
ACKNOWLEDGMENT OF FINANCIAL OR OTHER SUPPORT This activity is supported by Professional Educational grants and will be disclosed at the activity.
QUESTIONS ABOUT CME?Please contact the Office of CME at (215) 440-9300 or email@example.com.